Search research articles
Contact Us
Filters
Showing results (101-110 of 163) with videos related to
Page
of 17
Sort By:
The Journal of Investigative Dermatology
|
May 19, 2010
Early death from clinical stage I melanoma
A J Sober, C L Day, T B Fitzpatrick, et al.
The Journal of Investigative Dermatology
|
May 19, 2010
Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients
A J Sober, C L Day, T B Fitzpatrick, et al.
American Journal of Public Health
|
April 1, 1996
Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts
A C Geller, D R Miller, R A Lew, et al.
Journal of Spinal Disorders
|
May 6, 1999
Factors affecting lumbar spinal fusion
R K Snider, N K Krumwiede, L J Snider, et al.
Journal of the American Academy of Dermatology
|
August 1, 1990
Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society
V A Albert, H K Koh, A C Geller, et al.
British Journal of Pharmacology
|
March 1, 1995
Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor
S E Telford, A I Smith, R A Lew, et al.
Journal of General Internal Medicine
|
March 1, 1992
Use of health services before the diagnosis of melanoma: implications for early detection and screening
A C Geller, H K Koh, D R Miller, et al.
CA: a Cancer Journal for Clinicians
|
March 1, 1982
Cutaneous malignant melanoma: prognostic guidelines for physicians and patients
C L Day, M C Mihm, R A Lew, et al.
The Journal of Investigative Dermatology
|
June 1, 1983
Early death from clinical stage I melanoma
A J Sober, C L Day, T B Fitzpatrick, et al.
British Journal of Pharmacology
|
July 1, 1996
Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo
R A Lew, F Tomoda, R G Evans, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 163) with videos related to
Sort By:
Page
of 17
The Journal of Investigative Dermatology
|
May 19, 2010
Early death from clinical stage I melanoma
A J Sober, C L Day, T B Fitzpatrick, et al.
The Journal of Investigative Dermatology
|
May 19, 2010
Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients
A J Sober, C L Day, T B Fitzpatrick, et al.
American Journal of Public Health
|
April 1, 1996
Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts
A C Geller, D R Miller, R A Lew, et al.
Journal of Spinal Disorders
|
May 6, 1999
Factors affecting lumbar spinal fusion
R K Snider, N K Krumwiede, L J Snider, et al.
Journal of the American Academy of Dermatology
|
August 1, 1990
Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society
V A Albert, H K Koh, A C Geller, et al.
British Journal of Pharmacology
|
March 1, 1995
Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor
S E Telford, A I Smith, R A Lew, et al.
Journal of General Internal Medicine
|
March 1, 1992
Use of health services before the diagnosis of melanoma: implications for early detection and screening
A C Geller, H K Koh, D R Miller, et al.
CA: a Cancer Journal for Clinicians
|
March 1, 1982
Cutaneous malignant melanoma: prognostic guidelines for physicians and patients
C L Day, M C Mihm, R A Lew, et al.
The Journal of Investigative Dermatology
|
June 1, 1983
Early death from clinical stage I melanoma
A J Sober, C L Day, T B Fitzpatrick, et al.
British Journal of Pharmacology
|
July 1, 1996
Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo
R A Lew, F Tomoda, R G Evans, et al.
Page
of 17